Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (6418)	5/23/2002 4:17:50 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Yes, 8-2 in favor of approval. We can all heave a sigh of relief for the biotech sector here, although FDA approval is not guaranteed. (The non-biotech people are of course confusing the AC panel with the FDA - this doesn't at all mean that the FDA has suddenly become easier). I guess my prediction from a while back turned out correct: I think that the AC will vote to approve Amevive, but that there will be some dissension. Message 17452333 However I didn't put my money where my mouth was - I ended up sitting this one out altogether. So on that basis I decline to take any credit for the prediction. <g> Peter

To: Ian@SI who wrote (6418)	5/23/2002 4:21:38 PM
From: Czechsinthemail	Read Replies (1) \| Respond to of 52153

The BGEN news seem to trigger a buying stampede among biotechs today. BBH was up over 7%. Here's a news release: US FDA panel recommends Biogen psoriasis drug SILVER SPRING, Md., May 23 (Reuters) - A U.S. advisory panel on Thursday gave its backing for Biogen Inc.'s (NasdaqNM:BGEN - News) psoriasis treatment Amevive, a drug viewed as crucial for the company's future growth. The panel voted 8-2 that Amevive was safe and effective for treating chronic cases of psoriasis in adults. The Food and Drug Administration will consider the panel's opinion as it decides whether to clear Amevive for marketing in the United States. The agency usually follows its panels' advice. Biogen, a biotech company based in Cambridge, Massachusetts, currently has only one marketed product, multiple sclerosis treatment Avonex, which is facing new competition. Amevive is designed to treat psoriasis by targeting specific T-cells that play a critical role in the skin disorder, which causes scaling bumps and raised patches on the skin. Moderate to severe cases can lead to physical and social disabilities including depression, Biogen said. Current therapies are limited. Genentech Inc. (NYSE:DNA - News) and XOMA Ltd. (NasdaqNM:XOMA - News) are jointly developing a psoriasis treatment called Xanelim, and Immunex Corp. (NasdaqNM:IMNX - News) is testing its arthritis drug Enbrel for psoriasis.